The combined value of those assets on the for-sale list, which include Novartis' U.S. generics dermatology business, could reach $2 billion.
Takeda plans major cuts after $62 billion Shire buyout; Ascletis files for HK IPO under new listing rules; AZ hands Seroquel rights to Luye Pharma.
Samsung BioLogics is well on its way to becoming the world's largest contract manufacturer.
South Korea's PRP has acquires a 6,000 meter plant that can produce 2 million vials of the generic ingredient used in wrinkle fighter Botox.
A yearlong struggle for control of Chinese vaccine maker Sinovac Biotech has forced the company to suspend manufacturing of its hepatitis A vaccine.
Shire and Takeda have agreed on a deal. Now, it's up to the Japanese drugmaker to make the $62 billion deal pay off—and job cuts will be part of that.
AstraZeneca is back at it again with its asset sales. The company offloaded certain Seroquel rights to Luye Pharma for up to $538 million.
The solid-dose API operation of WuXi had its first visit by FDA inspectors at a new plant in Changzhou, China, and the company says it aced it.
Merck's Gardasil rollout in China helped the vaccine franchise grow sales 24% in the first quarter.
India's Aurobindo has submitted a $1.6 billion offer for Novartis' generic dermatology assets in the U.S., according to Livemint.
Teva said that while it doesn’t expect a sign-off for the drug by mid-June, it does foresee getting approval for a launch by the end of 2018.